Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA.
J Occup Environ Med. 2012 Jul;54(7):826-33. doi: 10.1097/JOM.0b013e31825b1bd2.
To respond to employer and payer interest in the extent to which productivity gains offset therapy costs by identifying clinical trials that did not include such measures and using their clinical data to impute productivity impact.
A PubMed search identified the sample of 25 clinical trials of musculoskeletal pain medications and antidepressants. Next, we applied regression coefficients, quantifying the empirical relationship between clinical measures to each trial's clinical outcomes data. This validated methodology provides estimates of Work Limitations Questionnaire Productivity Loss scores.
Based on imputation, musculoskeletal medications and antidepressants achieved median productivity gains of approximately 0.5% and 1.0%, respectively.
Accounting for productivity gains based on the Work Limitations Questionnaire could substantially influence cost-effectiveness results reported in the health economics literature.
通过确定未包含此类措施的临床试验，并使用其临床数据来推断生产力影响，以回应雇主和付款人对生产力收益是否足以抵消治疗成本的关注。
通过 PubMed 搜索，确定了 25 项肌肉骨骼疼痛药物和抗抑郁药的临床试验样本。接下来，我们应用回归系数，量化了每个试验的临床结果数据与临床测量之间的经验关系。这种经过验证的方法提供了工作限制问卷生产力损失评分的估计值。
根据推断，肌肉骨骼药物和抗抑郁药的生产力收益中位数分别约为 0.5%和 1.0%。
基于工作限制问卷的生产力收益核算可能会极大地影响健康经济学文献中报告的成本效益结果。
